Sartorius Stedim Biotech SA: Information on Document Availability
|
Sartorius Stedim Biotech SA
Aubagne, February 18, 2020
Sartorius Stedim Biotech: Information on Document Availability
Sartorius Stedim Biotech Group's Universal Registration Document 2019 is now available at:
It contains the following information: - Business development for fiscal 2019 and the 2020 forecast for the Sartorius Stedim Biotech Group - Consolidated financial statements for the year ended December 31, 2019
A profile of Sartorius Stedim BiotechSartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2019, the company employed approx. 6,200 people, and earned sales revenue of 1,440.6 million euros.
Phone: +49(0)551.308.1686; [email protected]
Regulatory filing PDF file Document title: Information on Document Availability Document: http://n.eqs.com/c/fncls.ssp?u=BHNACJUWUX |
| Language: | English |
| Company: | Sartorius Stedim Biotech SA |
| Avenue de Jouques | |
| 13781 Aubagne | |
| France | |
| Phone: | +33 44 284 5600 |
| E-mail: | [email protected] |
| Internet: | www.sartorius-stedim.com |
| ISIN: | FR0013154002 |
| Euronext Ticker: | DIM |
| AMF Category: | Additional regulated information to be pubicly disclosed under the legislation of a Member State / Terms of availability of a registration document or its updates |
| EQS News ID: | 977539 |
| End of Announcement | EQS News Service |
977539 18-Feb-2020 CET/CEST
